企業プロフィール

89bio, Inc. 株価・ニュース・カタリスト

ティッカー:: ETNB
取引所:: NASDAQ
セクター:: Biopharma
所在地:: United States

株価変動の要因

Current closing-price context is not available for ETNB.

企業概要

事業概要

89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.

所在地とセクター分類

Headquartered in the United States and listed on NASDAQ, 89bio sits in specialty biopharma.

ビジネスモデルの特徴

The business depends on clinical data, dose strategy, and whether the company can deliver a differentiated MASH profile.

バイオ業界での位置付け

89bio is one of the more closely watched liver-disease names because efficacy and safety can quickly change the story.

今後のカタリスト

89bio's catalysts are pegozafermin in MASH and severe hypertriglyceridemia, where the next data step can materially change the valuation. The company is still being judged on metabolic-disease execution.